Results 1 to 10 of about 8,194 (217)

Conventional heart failure therapy in cardiac ATTR amyloidosis [PDF]

European Heart Journal, 2023
Abstract Aims The aims of this study were to assess prescription patterns, dosages, discontinuation rates, and association with prognosis of conventional heart failure medications in patients with transthyretin cardiac amyloidosis (ATTR-CA).
Adam Ioannou, Yousuf Razvi, Steven Law
exaly   +8 more sources

Musculoskeletal manifestations associated with transthyretin-mediated (ATTR) amyloidosis: a systematic review [PDF]

BMC Musculoskeletal Disorders, 2023
Background Hereditary and wild-type transthyretin-mediated (ATTRv and ATTRwt) amyloidoses result from the misfolding of transthyretin and aggregation of amyloid plaques in multiple organ systems.
Emre Aldinc, Courtney Campbell, Finn Gustafsson, Abigail Beveridge, Richard Macey, Laura Marr, Catherine Summers, Dafang Zhang   +7 more
doaj   +2 more sources

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable [PDF]

Orphanet Journal of Rare Diseases, 2021
Background The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease.
Thomas H. Brannagan, Michaela Auer-Grumbach, John L. Berk, Chiara Briani, Vera Bril, Teresa Coelho, Thibaud Damy, Angela Dispenzieri, Brian M. Drachman, Nowell Fine, Hanna K. Gaggin, Morie Gertz, Julian D. Gillmore, Esther Gonzalez, Mazen Hanna, David R. Hurwitz, Sami L. Khella, Mathew S. Maurer, Jose Nativi-Nicolau, Kemi Olugemo, Luis F. Quintana, Andrew M. Rosen, Hartmut H. Schmidt, Jacqueline Shehata, Marcia Waddington-Cruz, Carol Whelan, Frederick L. Ruberg   +26 more
doaj   +2 more sources

Portuguese‐type amyloidosis (transthyretin amyloidosis, ATTR V30M). [PDF]

Journal of nephrology, 2003
J Nephrol. 2003 May-Jun;16(3):438-42. Portuguese-type amyloidosis (transthyretin amyloidosis, ATTR V30M). Lobato L. SourceDepartment of Nephrology, Santo António General Hospital, Porto, Portugal.
Lobato, L.
core   +3 more sources

Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review [PDF]

Orphanet Journal of Rare Diseases
Introduction Significant advances in the treatment of transthyretin (ATTR) amyloidosis has led to an evolving understanding of the epidemiology of this condition. This systematic literature review (SLR) aims to synthesize current evidence on epidemiology
Diego Delgado, Firas Dabbous, Nitin Shivappa, Faizan Mazhar, Eric Wittbrodt, Divya Shridharmurthy, Krister Järbrink   +6 more
doaj   +2 more sources

Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction? [PDF]

Cardiac Failure Review, 2020
Heart failure with preserved ejection fraction (HFpEF) comprises half of the heart failure population. A specific, but underdiagnosed, cause for HFpEF is transthyretin-derived (ATTR) amyloidosis.
Sebastiaan HC Klaassen, Dirk J van Veldhuisen, Hans LA Nienhuis, Maarten P van den Berg, Bouke PC Hazenberg, Peter van der Meer   +5 more
doaj   +4 more sources

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis). [PDF]

Int J Mol Sci, 2021
Transthyretin (TTR) amyloidogenesis involves the formation, aggregation, and deposition of amyloid fibrils from tetrameric TTR in different organs and tissues. While the result of amyloidoses is the accumulation of amyloid fibrils resulting in end-organ damage, the nature, and sequence of the molecular causes leading to amyloidosis may differ between ...
Gonzalez-Duarte A, Ulloa-Aguirre A.
europepmc   +4 more sources

Diagnosis and Treatment of AL and ATTR Amyloidosis. [PDF]

J Adv Pract Oncol, 2021
At JADPRO Live Virtual 2020, Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN®, FAAN, and Tiffany Richards, PhD, ANP-BC, AOCNP®, differentiated between AL and ATTR amyloidosis, discussed key considerations in selecting therapy, and identified ways that advanced practitioners can manage the supportive care needs of this patient population.
Faiman B, Richards T.
europepmc   +4 more sources

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis [PDF]

JACC: Basic to Translational Science, 2019
Summary: Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue.
Kathleen W. Zhang, MD, Keith E. Stockerl-Goldstein, MD, Daniel J. Lenihan, MD   +2 more
doaj   +3 more sources

Structure-Based Probe Reveals the Presence of Large Transthyretin Aggregates in Plasma of ATTR Amyloidosis Patients [PDF]

JACC: Basic to Translational Science
Summary: Amyloidogenic transthyretin (ATTR) amyloidosis is a relentlessly progressive disease caused by the misfolding and systemic accumulation of amyloidogenic transthyretin into amyloid fibrils.
Rose Pedretti, BS, Lanie Wang, BS, Anna Yakubovska, MS, Qiongfang S. Zhang, BS, Binh Nguyen, PhD, Justin L. Grodin, MD, Ahmad Masri, MD, Lorena Saelices, PhD   +7 more
doaj   +2 more sources